RxSight initiated with bullish view at Stifel, here’s why

Stifel initiated coverage of RxSight with a Buy rating and $40 price target. The firm is bullish on RxSight as a “true disruptor” in the attractive premium intraocular lens, or IOL, market, the analyst tells investors. The firm’s survey checks of 30 LAL users were positive, as the respondents expect strong intermediate and long-term LAL growth and share gains, the analyst added.